Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Editas Medicine Cmn (EDIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 650,849
  • Shares Outstanding, K 41,350
  • Annual Sales, $ 6,050 K
  • Annual Income, $ -97,180 K
  • 36-Month Beta 5.41
  • Price/Sales 108.41
  • Price/Cash Flow 0.00
  • Price/Book 3.18

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.42 +2.59%
on 07/18/17
18.25 -13.32%
on 06/26/17
-1.09 (-6.45%)
since 06/21/17
3-Month
13.12 +20.58%
on 05/31/17
20.73 -23.69%
on 05/02/17
-3.17 (-16.69%)
since 04/21/17
52-Week
12.43 +27.27%
on 11/03/16
29.20 -45.82%
on 03/14/17
-10.02 (-38.78%)
since 07/21/16

Most Recent Stories

More News
J.P. Morgan Vice Chairman Stephen Berenson Joins Flagship Pioneering

Flagship Pioneering, a fully-integrated life science innovation enterprise, today announced that Stephen Berenson has joined the firm as executive partner. The former vice chairman of investment banking...

SYRS : 19.32 (+5.29%)
AGIO : 57.17 (-0.10%)
MCRB : 13.74 (+1.03%)
JPM : 90.89 (-0.34%)
EDIT : 15.82 (+0.51%)
Today's Research Reports on Stocks to Watch: Valeant Pharmaceuticals and Editas Medicine

NEW YORK, NY / ACCESSWIRE / May 31, 2017 / Editas Medicine's shares plunged yesterday after a published paper in the scientific journal Nature Methods revealed that the genome editing tool CRISPR/Cas9,...

EDIT : 15.82 (+0.51%)
VRX : 17.50 (-0.57%)
What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?

Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.

AZN : 34.05 (+0.47%)
EDIT : 15.82 (+0.51%)
PFE : 33.48 (-0.18%)
MKGAF : 116.0000 (-0.42%)
Why Editas Medicine (EDIT) Might Surprise This Earnings Season

Investors are always looking for stocks that are poised to beat at earnings season and Editas Medicine, Inc. (EDIT) may be one such company.

EDIT : 15.82 (+0.51%)
Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from its pre-clinical hematopoietic stem cell (HSC) program confirming the potential for CRISPR-based editing...

EDIT : 15.82 (+0.51%)
Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?

Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.

AUPH : 6.55 (-0.76%)
CDTX : 8.00 (unch)
EDIT : 15.82 (+0.51%)
PRGO : 76.21 (+0.93%)
4 Drug Stocks Poised to Beat this Earnings Season

M&A and licensing deals as well as drug pricing issues are expected to remain in focus in 2017.

ENDP : 12.38 (+0.49%)
JNJ : 135.31 (-0.92%)
IMDZ : 9.95 (+6.42%)
LLY : 84.66 (-0.11%)
IONS : 56.39 (+0.95%)
EDIT : 15.82 (+0.51%)
GILD : 73.76 (+0.46%)
BIIB : 282.92 (+0.53%)
Editas Medicine to Present at Investor Conferences in May

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in May. Details are as follows:

EDIT : 15.82 (+0.51%)
Editas Medicine to Host Conference Call Discussing First Quarter 2017 Corporate Update and Results

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, May 15, 2017, at 5:00 p.m. ET to discuss a corporate update...

EDIT : 15.82 (+0.51%)
What's in Store for Immune Design (IMDZ) Stock in Q1 Earnings?

Immune Design Corp (IMDZ) is expected to report first-quarter 2017 results on May 9.

IMDZ : 9.95 (+6.42%)
IONS : 56.39 (+0.95%)
EDIT : 15.82 (+0.51%)
RHHBY : 32.2700 (+0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.

See More

Support & Resistance

2nd Resistance Point 16.59
1st Resistance Point 16.21
Last Price 15.82
1st Support Level 15.52
2nd Support Level 15.21

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.